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 Alzheimer’s disease (AD) is the most common form of dementia in the elderly. For 
more effective therapy early diagnostic markers could be beneficial. Therefore we compared 
one year old rats with adults and examined if changes in possible brain markers of AD 
preceeded memory decline. We also tested if vasopressin-deficient animals were useful 
model of AD as vasopressin has well known positive effect on memory and AD patient has 
decreased vasopressin production. 
We compared adult (3 month) and old (12 month), normal and vasopressin-deficient 
Brattleboro rats. To receive a comprehensive picture about their memory we examined their 
social discrimination, object discrimination and conditioned learning abilities (shuttle box).  
Amyloid precursor protein (APP), mitogen-activated protein kinase 1 (MAPK1), β-actin and 
tryptophan 2,3-dioxygenase 2 (TDO2) mRNA levels was measured by quantitative PCR. 
There was no difference between the memory of adult and aged groups. The 
vasopressin-deficient rats at both ages showed a weaker performance in the course of social 
and object discrimination tests and a higher escape failure during the shuttle box experiment. 
The brain marker mRNAs of the elder animals were higher than the levels of the adults, but 
the absence of vasopressin had no influence on them. 
Thus, the one year old rats showed elevated levels of AD-related markers, but 
memory deficits were observable only in vasopressin deficient animals. Vasopressin does not 
seem to have pathogenic role in AD. Changes in the studied markers might predict later 
symptoms, although further studies are required for confirmation.  
Keywords: APP, β-actin, MAPK1, memory, object discrimination, shuttle box, social 
discrimination, TDO2  
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1. Introduction 
Alzheimer’s disease (AD) is a heterogenous neurodegenerative disorder and the most 
common form of dementia worldwide. It is characterized pathologically by senile plaques, 
neurofibrillary tangles, neuronal loss, and clinically by a progressive cognitive decline. There 
is a growing body of evidence that the most beneficial effects of treatment might only be 
achieved in the preclinical stage of dementia, prior to the immense hallmarks of 
neurodegeneration [36]. Therefore early biological markers are very important [24]. The 
amyloid hypothesis of AD postulates that the initiating molecule of the disease is amyloid-, 
a proteolytic derivative of the amyloid precursor protein (APP) [51], ultimately leading to 
neuronal degeneration and dementia [25]. It is assumed that APP is an important protein for 
tissue repair and its expression is up-regulated following nerve damage [64]. Interestingly, 
the APP level of the human cerebrospinal liquor shows a positive correlation with the 
progress of age independently from any illness [10]. Beside amyloid-β, neurofibrillary 
tangles (NFT) are other hallmarks of AD [11]. NFT production is a result of abnormal 
hyperphosphorylation of the microtubule-associated protein tau and the mitogen-activated 
protein kinase (MAPK) plays a leading role in this abnormal hyperphosphorylation [27]. The 
β-actin has a relatively stable expression, but this molecule is considered to be involved in 
synaptogenesis, neuronal plasticity and clinical conditions like depression and AD, too [23]. 
The tryptophan 2,3-dioxygenase (TDO2) enzyme is a rate limiting factor in the metabolism 
of the neuro-immune modulator quinolinic acid [50] and this way promotes the 
neurodegenerative processes.  
During the course of aging some important changes are found in the human 
hypothalamus. Among others, the normal circadian ﬂuctuations seen in the number of 
vasopressin (AVP) neurons in the nucleus suprachiasmaticus of young subjects diminished in 
elderly subjects [38], thus an important role of AVP during the course of aging could be 
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supposed [14]. Although the main function of AVP is the antidiuresis in kidney, it plays a key 
role in hypothalamo-pituitary-adrenocortical (HPA) axis regulation, thereby in stress-related 
psychiatric diseases, like depression [31]. Depression can also be one of the earliest 
symptoms of AD [2]. Half of the AD patients suffer from minor or major depressive disorder, 
too [47, 56]. As the leading symptom of AD is the memory deficit [28], molecules that 
influence memory formation might have a pathogenic role. In connection with its role in 
circadian regulation [15] AVP might be such a molecule. Indeed, administration of AVP 
receptor antagonists resulted in memory impairment both in mice [3] and in rats [39]. The 
adult AVP-deficient Brattleboro rats showed reduced social discrimination ability which was 
improved by AVP administration [16]. Moreover, a signiﬁcant AVP decrease has been found 
in many brain regions of AD patients [20, 34]. A recent study in rats found centrally 
administered AVP protective against amyloid-β protein-induced memory decline in the 
Morris water maze test [42], supporting the beneficial effect of central AVP in the prevention 
and treatment of AD. 
We aimed to test if aging influenced the effect of AVP on memory and if the possible 
behavioral changes were underlined by alteration in Alzheimer’s related molecules. In this 
case AVP-deficient animals could be a useful model of Alzheimer`s disease. We compared 
adult (10-12 weeks old) and older (1 year old) AVP-deficient (di/di) and control (+/+) 
animals of the Brattleboro strain. This strain is due to a spontaneous mutation in the 
neurophysin region of the AVP gene resulting in abnormal AVP synthesis [53]. Previous 
studies on memory did not use older Brattleboro rats and the control animals were also 
questionable (see later) [4]. Our hypothesis was that aging will further enhance the impaired 
learning ability of AVP-deficient rats and it will be accompanied by enhanced mRNA level 
of APP, β-actin, MAPK1 and TDO2, which – according to our knowledge - were never 
examined in one-year-old rats. Thus, at the same time we tested also the possibility that 
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changes in possible brain markers of AD preceeded memory decline. As parietal lobe 
dysfunction is an important characteristic of early AD we took tissue samples from the 
parietal cortex [32].  
2. Material and methods 
2.1. Animals 
Male Brattleboro rats, naturally deficient in AVP were used in their adult (~330 g, 10-12 
weeks old) or older (~500 g, 1 year old) age. Rats were obtained from the local breeding
 
colony of the Institute of Experimental Medicine in Budapest,
 
Hungary started from breeder 
rats from Harlan, Indianapolis, IN, USA. The animals were kept under controlled laboratory 
conditions (21±1 ◦C, 50–70% humidity, 12 h light starting at 07:00 h) with commercial rat 
chow (Charles River, Budapest, Hungary) and tap water ad libitum.  
We compared the AVP deﬁcient homozygous recessive (di/di) rats with diabetes insipidus to 
normal homozygous dominant (+/+) control rats [68]. As Brattleboro rats originated from Long 
Evans strain approx. 50 years ago, it is not a proper control for AVP-deficiency. Our control, +/+ rats 
were bread out locally [68]. They are in close relationship with the AVP-deficient ones (heterozygous 
mothers are the daughters of +/+ mothers). The only difference is the point mutation in the AVP gene.  
The adult animals were sexually naive, and the older animals were sexually experienced 
breeder rats. To avoid possible confounding effect of social contact with other rats (e.g. 
hierarchy [61]) all experiments were performed on single-housed animals (approx. 1 week 
isolation).  
All manipulations of the animals were approved by
 
the local committee for animal health and 
care and performed
 
according to the European Communities Council Directive 
recommendations
 
for the care and use of laboratory animals (86/609/CEE). 
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2.2. Behavior 
2.2.1. Social discrimination test 
Olfactory memory was tested during the light phase between 9:00 am and 1:00 pm using the 
social discrimination procedure [17]. First, the rats were transferred to a new cage (41.3 x 26 
x 29.8 cm, GeoMaxi, Ferplast, Italy) with fresh bedding 1 h before starting the test. Each 
social discrimination test consisted of two 4 min exposures to juveniles in the new cage. 
During the first, sampling phase the adult animal was allowed to acquire the olfactory signal 
of a given juvenile (Juvenile 1). The little male or female Wistar rats were 25-30 days old. 
The observed animals do not regard them as rival, or prey in this age and body size. After 4 
min Juvenile 1 was removed and kept individually in a fresh cage with food and water ad 
libitum. After 30 minutes interval the adult was re-exposed to Juvenile 1 (old) together with a 
second, novel juvenile (Juvenile 2) (choice phase). The duration of the investigatory behavior 
of the adult towards each juvenile was measured separately by a trained observer blind to the 
animal’s age and genotype. To allow the observer to distinguish between the two juveniles, 
one of them was marked with green lines (Edding 30 permanent marker, odorless, green, 
Edding AG, Germany) at least 30 min before testing. To exclude the opportunity of 
preference or aversive reaction toward the marked animals we randomised the marking 
between Juvenile 1 and Juvenile 2. The tests were videotaped and the investigatory behavior 
was analysed by events recorder (H77). Investigatory behavior was defined as direct action 
towards the juvenile rat including anogenital sniffing, licking, hunting, pawing and close 
pursuing. A signiﬁcantly longer investigation duration of Juvenile 2 versus Juvenile 1 during 
choice phase is taken as an evidence for an intact recognition memory [17]. The 
discrimination index was calculated as follows: Discrimination index = time percentage 
Juvenile 2 / (time percentage Juvenile 1 + time percentage Juvenile 2) The result of the index 
changes between 0 and 1, where 0.5 = no discrimination. Normally the animals spend more 
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time with the new stimulus (novelty effect), thus the index below 0.5 is a sign of memory 
deficit.  
2.2.2. Object discrimination test 
For the object related equivalent of social discrimination we developed an experimental 
design comparable to the social paradigm in both time course and test settings. Two different 
objects were used instead of juveniles. A cat bedding filled blue round iron box (diameter: 
9.5 cm, height: 4 cm) and comparable size transparent glass bottle (diameter: 7 cm, height 7.5 
cm) were used. One of this objects (Object 1) was presented for 4 min (sampling phase), than 
removed, and 30 min later the same (Object 1) and a different object (Object 2) were 
introduced to the rat for 4 min. The objects were thoroughly cleaned with water before each 
test. The tests were videotaped and analysed as mentioned before. In behavior directed 
towards the object we distinguished sniffing and gnawing as an important component. To 
exclude object preference the two objects were randomly used as Object 1 or Object 2, and to 
exclude place preference the place of Object 1 and Object 2 were also randomised. 
Discrimination index was calculated as previously. 
2.2.3. Shuttle box test 
The shuttle-box apparatus consisted of two identical compartments (30 x 30 x 30 cm each) 
separated by a barrier with a gate in the middle [5]. It was placed in an isolated room. 
Animals were trained to cross the barrier under the duration of a flashlight (conditioned 
stimulus, CS). If they fail to do so they were punished with a footshock (unconditioned 
stimulus, US) of 0.3 mA delivered via the grid floor of the shuttle-box. Each trial consisted of 
three periods: (1) Resting period (intertrial interval) was constant. Intertrial crossings (IC) 
were not punished. (2) CS period when CS was presented for a maximum of 10 sec, 
signalling the impending footshock. If the rat responded within this 10 sec period (referred to 
conditioned avoidance response, CAR), the CS was terminated and the next trial started again 
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without delivery of US. (3) If the animal failed to respond to CS, the footshock (US) was 
applied together with the light until the rat responded or for a maximum of 5 sec (CS + US 
period). In case the rat failed to escape the US within 5 sec, it was considered as escape 
failure (EF). The rats got 100 trials in daily sessions for 5 consecutive days. The number of 
CAR, EF and IC were automatically recorded during the five daily sessions. On the days of 
the experiments animals were transported in their home cages to the laboratory 60 min prior 
to the shuttle-box session. All parts of the experiment were made at comparable periods of 
the day during the light period. On the first day the animals were allowed to habituate to the 
environment for 5 minutes. 
2.3. Molecular changes 
Samples and RNA preparation 
Naive animals were anaesthetized intraperitoneally by 10% chloralhydrat and after 
transcardial perfusion by 2-4°C physiological saline both hemispherium were removed and 
samples were taken from the parietal cortex (30 mg/animal) on wet ice and were stored 
immediately on -80C until processing.  
Total RNAs were extracted and puriﬁed using NucleoSpin RNA puriﬁcation kit (Macherey-
Nagel, Durren, Germany) according to the manufacturer’s instructions. We homogenized 30 
mg brain tissue with 350 µl RA1 buffer and then we lysed the cells using 3.5 µl 
mercaptoethanol. We filtered the lysatum on the first filter by centrifugation (60 s, 1000 g), 
then we added 350 µl 70% ethanol to it and centrifuged again through the second filter (30 s, 
11000 g). At this time the nucleic acids tied on the filter. We salted out the silica membrane 
with 350 µl membrane salt buffer (desalting buffer, MDB). Than we gave 10 µl rDNase, 90 
µl rDNase reaction buffer and 95 µl rDNase reaction mix to the solution, incubated on room 
temperature for 15 minutes. Then we washed it and desiccated the membrane by spin drying 
with 200 µl RA2 buffer (30 s, 11000 g), then with 600 µl RA3 buffer (30 s, 11000 g), and 
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finally again 250 µl RA3 buffer (2 minutes, 11000 g). We dissolved the solution containing 
full cell RNA from the membrane with 60 µl ribonuclease free water (1 minute, 11000 g). 
Finally we added 0.5 µl ribonuclease inhibitor to the solutions and stored it on –80 °C until 
use. 
Reverse transcriptase polymerase chain reaction (RT-PCR) 
We measured the full RNA concentration of the solutions with a spectrophotometric method, 
nanodrop apparatus. We added 15 µl reverse transcription cocktail [reverse transcriptase (1.5 
µl), DNA-polimerase, monomer (1.2 µl), random primer one (3 µl), RT buffer (3 µl), 
ribonuclease inhibitor and bidistilled water (4.8 µl) onto the 2 µg/15 µl concentration diluted 
RNA solutions. The primers were the follows:  
APP  forward: 5’-CCC CAA GAT CCG GTT AAA CT-3’  
reverse: 5’-TAC TTG TCG ACT GCG TCA GG-3’  
MAPK1 forward: 5’-CCA AGC TCA ACC GTC TCA TC-3’  
   reverse: 5’-GGC TGG TAG GGT AGT TGA TGC-3’ 
β-actin forward: 5’-CCC GCG GAG TAC AAC CTT CT-3’  
 reverse: 5’-CGT CAT CCA TGG CGA ACT-3’  
TDO2 forward: 5’-TGT AGC CGT GAC TGA TGT TCA GA-3’  
reverse: 5’-ACA GGT ACA AGG TGT TCG TGG AT-3’  
GAPDH forward: 5’-AGA TCC ACA ACG GAT ACA TT-3’  
   reverse: 5’-TCC CTC AAG ATT GTC AGC AA-3’ 
The reverse transcriptase synthetized copy DNA (cDNA) from the full cell mRNS during the 
polymerase chain reaction, then we gave 10 µl Roche SYBR Green Mix, 1 µl primer to 9 µl 
template cDNA. The RT-PCR machine (Corbett 3000 RT-PCR) defined the mRNS quantities 
in the original solutions. 
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In the course of data evaluation we applied the ∆∆Ct method [33]. The reference gene was 
the glyceraldehyde 3-phosphate dehydrogenase (GAPDH). All results are normalized to the 
values of adult +/+ rats. 
2.4. Statistical analysis 
The results are expressed as mean + S.E.M. Statistical significance was evaluated by two way 
analysis of variance (ANOVA; discrimination sample phase, discrimination index, brain 
markers; levels age and genotype) or repeated measure ANOVA (discrimination tests, shuttle 
box; time as within factor) followed by Neumann Keuls post hoc test, or evaluated by single 
sample t-test (in case of discrimination index) using Statistica 9.0 software (StatSoft, Tulsa, 
USA). A p value of less than 0.05 is considered to be significant. 
3. Results 
3.1. Behavior 
3.1.1. Social discrimination test 
During the whole social discrimination test (sampling + choice) the adult rats spent 
significantly more time with the juveniles, than the old ones based on repeated measure 
ANOVA (age F(1,37)=6.21, p<0.05) (Fig.1A). During the sample phase there was only a 
marginally significant effect of age by factorial ANOVA (age F(1,45)=3.08 p=0.08). At the 
same time during the choice phase the age had a significant effect by repeated measure 
ANOVA (age F(1,37)=11.97 p<0.01). In point of discrimination the time spent with old 
(juvenile 1) or new (juvenile 2) juveniles was significantly different by repeated measure 
ANOVA (old-new F(1,37)=13.44 p<0.01), but the genotype just marginally influenced this 
parameter (old-new x genotype F(1,37)=3.54 p=0.07).  
The discrimination index, originated from the time percentages of the choice phase, 
significantly differed between the genotypes (genotype F(1,37)=4.85 p<0.05), but the age had 
no effect by factorial ANOVA (Fig.1B). If we examine the difference of the discrimination 
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index from 0.5 (0.5 = not discrimination) by single sample t-test, we observed that the AVP-
deficient animals (di/di) were unable to discriminate (adult +/+: p<0.05; old +/+: p<0.05; 
adult di/di: p=0.78; old di/di: p=0.19). 
3.1.2. Object discrimination test 
During the whole object discrimination test (sampling + choice) the AVP-deficient 
rats spent significantly more time with the objects, than the +/+ ones based on repeated 
measure ANOVA (genotype F(1,30)=16.94, p<0.01) (Fig.2A). Both during the sampling phase 
(genotype by factorial ANOVA F(1,35)=16.34, p<0.01) and the choice phase alone (genotype 
by repeated measure ANOVA F(1,30)=11.83 p<0.01) the effect of genotype remained 
significant. In point of the discrimination there was a significant difference between the time 
spent with old (object 1) and new (object 2) object during the choice phase by repeated 
measure ANOVA (old-new F(1,30)=18.03 p<0.01) and this effect was different between the 
two genotypes (old-new x genotype F(1,30)=9.26 p<0.01).  
The discrimination index significantly differed between the two genotypes (genotype 
by factorial ANOVA F(1,30)=28.84 p<0.01) without any influence of age (Fig.2B). Based on 
the difference of the discrimination index from 0.5 by single sample t-test the AVP-deficient 
(di/di) animals were unable to discriminate (adult +/+: p<0.01; old +/+: p<0.01; adult di/di: 
p=0.94; old di/di: p=0.33).  
3.1.3. Shuttle box test 
 In case of intertrial crossing (IC) the two genotypes showed significant difference 
from each other (genotype F(1,35)=20.73, p<0.01) (Fig.3A). This parameter was higher in the 
AVP-deficient rats. The effect of the time was also significant (time F(4,140)=11.78, p<0.01) 
being the IC levels higher at later time-points. The effect of genotype was even more 
pronounced in the course of the experiment (genotype x time F(4,140)=6.80, p<0.01).  
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The conditioned avoidance response (CAR) differed between the two genotypes, too 
(genotype F(1,35)=15.30, p<0.01), being higher in the AVP-deficient rats (Fig.3B). The effect 
of the time was also significant (time F(4,140)=11.60, p<0.01).  
The escape failure (EF) differed also between the two genotypes (genotype 
F(1,35)=9.31, p<0.01), being higher in AVP-deficient rats (Fig.3C). The effect of the time was 
also significant (time F(4,140)=19.04, p<0.01), but the effect of genotype became smaller with 
time (genotype x time F(4,140)=3.22, p<0.01). There was a marginally significant effect of age 
x time interaction (age x time F(4,140)=2.02, p=0.09), with higher levels in old animals.  
3.2. Molecular changes 
The relative quantity of all the measured mRNA (APP, MAPK1, β-actin and TDO2) 
were significantly higher in the cerebral cortex of the 1 year old than adult animals (age APP 
F(1,23)= 62.81, p<0.01; MAPK1 F(1,26)= 4.33, p<0.05; β-actin F(1,24)= 35.20, p<0.01; TDO2 
F(1,26)= 48.24, p<0.01) without any effect of the genotype or interaction between age and 
genotype (Fig.4A-D).  
4. Discussion 
During the memory tests the AVP-deficient rats showed weaker performance 
independently of the age, while AD-related molecular markers were higher in older rats 
independently from the genotype. Thus, we were unable to support our first hypothesis, that 
AVP-deficient animals are good AD models, but we found that in 1 year old rats the changes 
in examined brain markers preceeded memory decline. 
Some authors reported memory deficits already in 1 year old rats [46]. As we assumed 
a further decrease in AVP-deficient rats, we did not use older animals with more pronounced 
memory disturbances. In our hand the 1 year old rats did not show any decline in memory 
traces compared to the adult population, although the results of the studied AD markers were 
already pathological. This could prompt further studies on an early diagnosis.  
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The social and object discrimination tests investigate short term, stressless memory 
processes, while shuttle box tests long term, stressfull learning. In accordance with the 
literature the AVP-deficient animals showed weaker discrimination abilities, than the normal 
ones [7, 16]. Previous studies used only adult animals, but – despite our expectations – aging 
did not enhance the memory disturbances of the AVP-deficient rats. Data in the literature on 
the results of avoidance tests are not consistent (e.g. no effect: [9]; memory deficit: [63]; 
prolonged extinction: [29]). The findings obtained in the shuttle box test in the present 
experiments were also contradictory. Both the adult and aged di/di rats showed worse escape 
failure, however their conditioned avoidance response (CAR) was superior to control 
animals. Take into consideration the ubiquiter role of AVP in our body [19], many other 
processes may confound the shuttle box performance of Brattleboro rats. (1) Although 
decline in activity is an important problem of human aging and can be found also in animals 
[45, 55], it is not a core symptom of AD and cannot be always detected in older rats [46]. On 
the contrary, higher physical activity seems to be protective against AD [6]. Enhanced 
activity of the di/di animals was reflected by enhanced sampling time in the object 
discrimination task and increased intertrial crossing (IC) during shuttle box experiment. 
Although in our previous experiments we could not detect any hyperactivity [37],  some other 
authors found Brattleboro rats to be hyperactive in a novel environment already in their 10-
day-old age [12, 54]. Enhanced locomotion can lead to higher CAR values independently 
from any memory processes. (2) AVP is an important regulator of the HPA axis, which 
consist from corticotropin-releasing hormone (CRH) in the hypothalamus, 
adrenocorticotropin in the pituitary and glucocorticoids in the adrenal cortex. The 
glucocorticoid hypothesis of aging and AD proposed that chronic exposure to glucocorticoids 
induced hippocampal atrophy with a decline in learning abilities [30]. Aged-superior learners 
had lower expression of glucocorticoid receptor and CRH mRNA in the hypothalamus 
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compared with other groups [35]. During the critical perinatal period the Brattleboro rats 
have higher resting glucocorticoid levels [66], which could contribute to their worse 
discrimination abilities later in life. On the contrary, different stressors, like the footshock 
during the shuttle box testing, may induce lower HPA axis reactivity [67]. Lower 
glucocorticoid levels can be accompanied by reduced inactivity in the shuttle box [1]. (3) The 
time spent in inactive posture (immobility) depends also on the subject`s temperament and 
coping style. The well-known depression test, forced swimming measures also the coping of 
the animals, however some authors suggested that it reflected effects of learning and memory 
rather than effects of despair or depression [65]. According to these assumptions the 
diminished immobility time of AVP-deficient rats during the forced swimming test [37] 
could be interpreted as changes in temperament [8, 26], more active coping style or even 
learning disabilities. Other depressive-like symptoms, like anhedonia, which is also changed 
in the Brattleboro rat [48], may also influence memory processes. 
As far as we know AD-related markers were never tested in AVP-deficient 
Brattleboro rats, and the studied markers were not examined in 1 year old „normal” rats 
either. According to the amyloid hypothesis APP is the initiating molecule of AD. Although 
several authors emphasize the involvement of APP metabolism in normal aging and AD [40], 
our results suggest that altered APP expression may also contribute. Literary data referred to 
AVP and APP interaction [41, 59], which we failed to confirm.  
The MAPK pathway is a key regulator of pro-inflammatory cytokine biosynthesis, which 
may contribute to the chronic low-grade inflammation observed with aging  [43]. We found a 
small increase in the MAPK mRNA level in old rats, which was more pronounced in AVP-
deficient animals. Signalisation cascade of AVP may include the MAPK pathway as well 
[44]. Although an elevated MAPK expression in old di/di rats seems to be contradictory, this 
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is not the only pathway for AVP and many other molecules may manipulate the MAPK 
cascade.  
The β-actin, a non-muscle cytoskeletal protein, has a relatively stable expression, therefore it 
is worldwide applied as a reference gene in the course of PCR [49]. Newer data indicated that 
β-actin is differentially expressed in the brain specimens of both AD and control subjects 
[23]. Indeed, the results of recent research in the pathomechanism of AD emphasize the 
significance of cytoskeletal changes [18]. Remodelling of the cytoskeletal architecture is a 
basic phenomenon in neuronal plasticity [58]. Despite previous report on constant -actin 
gene expression in aging [60], we found an elevated level in old rats, perhaps due to some 
methodological differences. Changes in actin remodelling may influence the neurotransmitter 
release, among others the secretion of AVP [62].  
The TDO2 enzyme plays a role in the transformation of the tryptophan to kynurenine [57] 
and increased concentrations of kynurenine metabolics leads to neurotoxic effects [52]. 
Regarding AD pathomechanism post mortem immunocytochemistry in the hippocampus of 
AD patients revealed elevated TDO2 levels [21] and amyloid-β treatment increased TDO2 
expression [22]. Thus, elevated TDO2 level in one year old rats might anticipate pathological 
changes. Although Comai et al. found a decline in the enzyme activities involved in 
tryptophan metabolism in old Sprague-Dawley rats compared to 2-3 month old ones [13],  it 
may be explained with methodological differences.  
5. Conclusions 
Our finding on early appearance of specific markers before appearance of any 
memory decline may prompt further studies and in the long run can be helpful in early 
diagnosis. The positive impact of AVP on memory was confirmed, thus it can be a useful 
cognitive enhancer. AVP-related other psychological functions like circadian clock, activity, 
stress and coping may also contribute to its positive effect on AD. As the absence or presence 
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of AVP did not influence the levels of AD-related markers, AVP decrease in AD patients 
seems to be more likely the result rather than the cause of AD development. However, we 
cannot close out the possibility that AVP effects the processing/metabolism of these factors 
rather that their mRNA levels.   
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Social discrimination test. n=7-13. A. Time percent spent with the juveniles during the 
sample and the choice phases. B. Discrimination index = time percentage with juvenile 2 / 
(time percentage with juvenile 1 + time percentage with juvenile 2). Abbreviations:  *p<0.05, 
**p<0.01 vs. juvenile 1., #p<0.05 vs. 0.5 (no choice). 
Fig.2 
Object discrimination test. n=7-10. A. Time percent spent with the objects during the sample 
and the choice phases. B. Discrimination index (= time percentage Object 2 / (time 
percentage Object 1 + time percentage Object 2)). Abbreviations: $p<0.05 vs. +/+; **p<0.01 
vs. object 1.; ##p<0.01 vs. 0.5 (no choice). 
Fig.3 
Shuttle box test. n=7-12. A. Intertrial crossing. B. Conditioned avoidance response. C. Escape 
failure. Abbreviations: $p<0.05, $$p<0.01 vs. +/+; +p<0.05, ++p<0.01 vs. day 1.; **p<0.01 
vs. adult 
Fig.4  
Alzheimer`s markers’ mRNA levels in comparison to adult, 3 month old +/+ animals 
calculated by the 2
-∆∆Ct
 method with glyceraldehyde 3-phosphate dehydrogenase (GAPDH) 
standard. n=6-10. A. Amyloid precursor protein (APP). B. Mitogen-activated protein kinase 1 
(MAPK1). C. β-actin. D. Tryptophan 2,3-dioxygenase 2 (TDO2). Abbreviations: *p<0.05, 
**p<0.01 vs. adult; $p=0.05 vs. +/+. 
